# Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

> **NCT01770145** · PHASE4 · COMPLETED · sponsor: **MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals** · enrollment: 127 (actual)

## Conditions studied

- Parkinson's Disease
- Motor Symptoms
- Akinesia
- Hypomobility
- Delayed Levodopa Onset

## Interventions

- **DRUG:** APOKYN
- **DRUG:** L-dopa
- **DRUG:** Trimethobenzamide

## Key facts

- **NCT ID:** NCT01770145
- **Lead sponsor:** MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01770145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01770145, "Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01770145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*